CleanCells
Private Company
Funding information not available
Overview
Clean Cells is a specialized, revenue-generating CDMO/CRO providing critical analytical testing and bioproduction services for the biologics and advanced therapy sectors. The company has established a strong reputation for quality, holding GMP certification and undergoing FDA Pre-Approval Inspections, which positions it as a trusted partner for global pharmaceutical companies. Backed by the private equity group Archimed since 2018 and having recently expanded to the US via acquisition, Clean Cells is scaling its capacity and service offerings to capitalize on the growing demand for outsourced development and manufacturing services in innovative therapeutic areas.
Technology Platform
Integrated CDMO/CRO service platform offering cGMP/GLP-compliant cell & virus bank manufacturing, viral vector production (via Naobios), and a comprehensive suite of quality control analytical testing (including specialized karyotyping via Karyologic).
Opportunities
Risk Factors
Competitive Landscape
Clean Cells competes in a fragmented but competitive market against large, global CDMOs (e.g., Lonza, Catalent, Thermo Fisher) and numerous niche specialists. Its differentiation lies in its deep expertise in virology and cell banking, integrated service offering from manufacturing to QC, and strong regulatory track record in Europe and the U.S., particularly for advanced therapies.